丁忠仁(1968～)， 河南淮滨人。复旦大学上海医学院研究员，博士生导师。美国血液学会(ASH)、国际血栓与止血学会(ISTH)会员。国家自然科学基金心血管药理专业同行评议专家。于1990年、1993年和1998年分别从河南医科大学、中山医科大学分别获得医学学士、硕士和博士学位。1993年7月 - 1995年8月在广州白云山制药总厂药物研究所从事抗生素的新药研发。1998年9月起在北京协和医院从事”纤溶酶原激活物抑制剂1 （PAI-1）多态性的研究”，2000年8月被评为“副研究员”。2000年8月起在在美国天普大学医学院Sol Sherry血栓研究中心从事血小板ADP受体的激活机制和以P2Y12受体为靶点的抗血小板药研究。2007年9月起在复旦大学上海医学院从事科研、教学工作。主要研究血小板激活的机制、抗血小板药作用机理和以P2Y12受体为靶点的抗血小板药的研发。与北京化工大学合作，首次报道了一种同时作用于血小板P2Y12受体和磷酸二酯酶、具有抗血小板活性的全新化合物BF0801。通过对BF0801进行结构改造，得到一种作用机制类似、活性更强的新化合物BF061，其抗血栓活性和氯吡格雷相似（小鼠肠系膜动脉FeCl3损伤血栓模型），但出血副作用更小。BF061的抗血栓作用同时被加拿大McMaster大学证实（小鼠提睾肌动脉激光损伤血栓模型）。在2011年7月在日本京都举行的“第23届国际血栓与止血学会大会” （International Society on Thrombosis and Haemostasis ⅩⅩⅢ Congress，ISTH 2011）上，该课题组抗血小板药的研究工作同时获得两项“青年研究学者奖”（Young Investigator Award)。承担国家自然科学基金（面上项目）5项、上海市科委“浦江计划”人才项目1项、科技部和上海市科委新药创制子课题各1项， 2008年首批首轮入选“上海高校特聘教授”(东方学者)。Hu L, Chang L, Zhang Y, Zhai L, Zhang S, Qi Z, Yan H, Yan Y, Luo X, Zhang S, Wang Y, Kunapuli SP, Ye H, *.Platelets Express Activated P2Y12 Receptor in Patients with Diabetes. 2017; Epub ahead of print (doi: 10.1161/CIRCULATIONAHA.116.026995; IF: 19.3)
Jianqin Ye, Lili Zhai, Shenghui Zhang, Yan Zhang, Leilei Chen, Liang Hu, Si Zhang, *. Dl-3-n-butylphthalide inhibits platelet activation via inhibition of cPLA2-mediated TXA2 synthesis and phosphodiesterase. 2015; 26(8): 736 - 44 ( IF: 3.2)Si Zhang, Shenghui Zhang, Liang Hu, Lili Zhai, Ruyi Xue, Jianqin Ye, Leilei, Chen, Jozef S. Mruk, Guanjun Cheng, Satya P. Kunapuli, *. Nucleotide-Binding Oligomerization Domain 2 Receptor Is Expressed in Platelets and Enhances Platelet Activation and ThrombosisIs. 2015; 131(13): 1160 - 1170 (Featured work with an editorial; IF: 17.2)Lei Liu, Jian Li, Yan Zhang, Shenghui Zhang, Jianqin Ye, Zhichao Wen, Jianping Ding, Satya P. Kunapuli, Xinping Luo*, *. Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory.  2014; 134(4): 866 - 76 (IF: 2.45)SH Zhang, Y Zhang, J Shen, S Zhang, L Chen, J Gu, G Cheng, JS Mruk, L Zhu, SP Kunapuli, *. Tumor vascular disrupting agent DMXAA inhibits platelet activation and thrombosis via inhibition of TXA2 signaling and phosphodiesterase2013; 11(10): 1855 - 1866 (IF: 5.6)S Zhang, J Ye, Y Zhang, X Xu, J Liu, SH Zhang, SP Kunapuli, . P2Y12 protects platelets from apoptosis via PI3k-dependent Bak/Bax inactivation. 2013; 11(1): 149 -160 (IF: 5.6)Y Zhang, J Ye, L Hu, S Zhang, SH Zhang, Y Li, SP Kunapuli, . Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12 receptor. 2012; 10(10): 2149 - 2157 (IF: 6.1)Pan C，Wei X，Ye J，Liu G，Zhang S，Zhang Y，Du H，. BF066, a novel dual target antiplatelet agent without significant bleeding. 2012; 7: e40451 (IF: 3.7)Guocheng Liu, Jiaxi Xu, Ning Chen, Si Zhang, Hongguang Du. Synthesis of N6-alkyl(aryl)-2-alkyl(aryl)thioadenosines as antiplatelet agents. 2012; 53: 114 - 123 (IF: 3.5)Liang Hu, Zhichao Fan, Hongguang Du, Ran Ni, Si Zhang, Kanhua Yin, Jianqin Ye, Yan Zhang, Xunbin Wei, Xiaohui Zhang, Peter L. Gross, Satya P. Kunapuli, . BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase. 2011; 106(6): 1203 - 14 (IF: 5.0)Guocheng Liu, Jiaxi Xu, Ki Chul Park, Ning Chen, Si Zhang,, Feng Wang，Hongguang Du. Novel synthesis approach and antiplatelet-activity evaluation of 6-alkylamino-2,4-dialkyl(aryl)thiopyrimidines. 2011; 67: 5156 - 5161 (IF: 3.0)Zhang S, Hu L, Du H, Guo Y, Zhang Y, Niu H, Jin J, Zhang J, Liu J, Zhang X, Kunapuli SP,. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism. 2010; 104(4): 845 – 57 (cover figure; IF: 4.7), Yamini S. Bynagari, Sripal R. Mada, Joseph A Jakubowski, Satya P. Kunapuli. Involvement of extracellular cysteines and oligomeric structures in P2Y12 receptor antagonizing effects of clopidogrel and prasugrel. 2009; 7(1): 232 – 4 (IF: 6.1), Soochong Kim, Satya P. Kunapuli. Identification of a potent P2Y12 receptor inverse agonist at constitutively active mutant of human P2Y12 receptor. 2006; 69(1): 338 - 345 (IF: 4.5), Florin Tuluc, Kavita R. Bandivadekan, Lili Zhang, Jianguo Jin, Satya P. Kunapuli. Arg333 and Arg334 in the C-terminus of the human P2Y1 receptor are crucial for Gq coupling. 2005; 288(3): C559 - 67 (IF: 3.9), Jia-Qi Pan. Distribution of PAI-1 promoter 4G/5G polymorphism in Chinese and functional characterization using a luciferase reporter vector. 2005; 84(3): 183 - 187 (IF: 2.2)Haripriya Shankar, Swaminathan Murugappan, Jianguo Jin, Soochong Kim，, Kevin Wickman, Satya P. Kunapuli. Role of G-protein gated inwardly-rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses. 2004; 104(5):1335 - 43 (IF: 9.8)John Meshki, Florin Tuluc, Ovidiu Bredetean, , Satya P. Kunapuli. Molecular mechanism of nucleotide-induced primary granule release in human neutrophils: role for the P2Y(2) receptor. 2004; 286(2): C264 - 271 (IF: 3.9)Satya P. Kunapuli, , Robert T. Dorsam, Soochong Kim, Swaminathan Murugappan, Todd M. Quiton. ADP receptors-Targets for developing antithrombotic agents. 2003; 9(28): 2303 - 16 (IF: 5.5), Soochong Kim, Robert T. Dorsam, Jianguo Jin, Satya P. Kunapuli. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, C17 and C270. 2003; 101(10): 3908 - 3914 (IF: 10.1) 